BidaskClub upgraded shares of Amyris (NASDAQ:AMRS) from a sell rating to a hold rating in a research note issued to investors on Friday, June 8th.
Several other research analysts have also recently commented on AMRS. Zacks Investment Research upgraded shares of Amyris from a hold rating to a buy rating and set a $7.50 target price for the company in a research report on Wednesday, May 2nd. B. Riley set a $10.00 price target on shares of Amyris and gave the stock a buy rating in a research note on Tuesday, May 29th. ValuEngine lowered shares of Amyris from a buy rating to a hold rating in a research note on Friday, June 1st. Finally, HC Wainwright set a $15.00 price target on shares of Amyris and gave the stock a buy rating in a research note on Tuesday, May 15th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. The company has an average rating of Hold and a consensus price target of $9.13.
NASDAQ AMRS opened at $5.59 on Friday. Amyris has a 52 week low of $1.86 and a 52 week high of $7.30. The company has a quick ratio of 0.62, a current ratio of 0.67 and a debt-to-equity ratio of -0.35. The stock has a market capitalization of $275.97 million, a price-to-earnings ratio of -1.83 and a beta of 0.07.
Amyris (NASDAQ:AMRS) last posted its earnings results on Monday, May 14th. The biotechnology company reported ($1.79) EPS for the quarter, missing the consensus estimate of ($0.48) by ($1.31). The business had revenue of $23.00 million for the quarter, compared to analysts’ expectations of $24.12 million. During the same period last year, the business posted ($0.13) EPS. The company’s revenue was up 77.2% compared to the same quarter last year. equities analysts expect that Amyris will post -1.92 earnings per share for the current year.
In related news, major shareholder (Mauritius) Pte Ltd Maxwell sold 95,162 shares of the stock in a transaction that occurred on Monday, May 7th. The shares were sold at an average price of $6.54, for a total transaction of $622,359.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 21.80% of the stock is owned by corporate insiders.
Several large investors have recently modified their holdings of the stock. Millennium Management LLC purchased a new stake in shares of Amyris in the 1st quarter valued at approximately $1,643,000. Hudson Bay Capital Management LP purchased a new stake in shares of Amyris in the 4th quarter valued at approximately $451,000. Compagnie Lombard Odier SCmA lifted its position in shares of Amyris by 60.0% in the 4th quarter. Compagnie Lombard Odier SCmA now owns 104,000 shares of the biotechnology company’s stock valued at $390,000 after acquiring an additional 39,000 shares in the last quarter. Crown Advisors Management Inc. purchased a new stake in shares of Amyris in the 1st quarter valued at approximately $669,000. Finally, JPMorgan Chase & Co. purchased a new stake in shares of Amyris in the 1st quarter valued at approximately $655,000. Institutional investors and hedge funds own 23.72% of the company’s stock.
Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.